Compare Biogen Inc (BIIB) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs F5 Inc — how do they compare? Biogen Inc trades at $206.57 (market cap $30.13B), while F5 Inc trades at $419.13 (market cap $23.44B). The key difference: Biogen Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIIB | FFIV | |
|---|---|---|
Market Cap | $30.13B | $23.44B |
Sector | Health | Technology |
52-Week High | $216.63 | $431.26 |
52-Week Low | $128.93 | $223.99 |
Enterprise Value | $37.20B | $22.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
F5 (FFIV) stock trades at $417.70, up 1.88% with bullish technical signals and strong earnings beats. Recent Q3 2026 results showed EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. The company raised its fiscal outlook, reflecting robust demand for application security and AI infrastructure. Key support lies at $411, with resistance at $422.
Outlook remains positive due to consistent earnings outperformance and raised guidance, though valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus price target of $430.43 implies moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
